Patient Investors Can Prosper in The Long Term by initiating Positions in Psychedelic Stocks such as Minerco Inc (MINE), MindMed (MMEDF) and Numinus Wellness Inc. (LKYSF)

While the psychedelic industry is still in its early stages, the promising potential of psychedelic medicine drug products has attracted the interest of savvy investors that’s because these psychedelics stocks offer an emerging investment opportunity.

Investors love a good story. And legalizing psychedelic drugs to combat the growing societal challenge that is mental health is as good as it gets.

Some of the earlier research and studies on psychedelics are expected to be released by mid-2021, and investors are already getting ahead of this in optimistic anticipation. This is evident in the valuations of some of these companies, which in some cases are already reaching a billion dollars.

Now, psychedelic startups, backed by investors dangling money and stock listings, are jumping in.

Regulatory support and encouraging research outcomes sent these stocks through the roof late last year. To name a few, Minerco Inc. soared a notable 3000%, Mind Medicine, surged a massive 860% and Numinus Wellness Inc., 1500% in 2020.

Minerco, Inc. (OTC: MINE), a Jamaican-based magic mushrooms company that’s been focusing on psychedelic therapies, is the world’s first publicly traded company specializing in growing, research, production and distribution of psilocybin mushrooms and marketing worldwide.

Last month, Global Trac Solutions, Inc. (OTCPink: PSYC) (“Global” “PSYC” or the “Company”) a digital media leader within the emerging sector of medicinal psychedelics, announced that the Company has entered into a Joint Venture Partnership (the “JV”) with Minerco, Inc. (OTC: MINE) (“MINE”), a Jamaican-based company specializing in growing, research, production and distribution of psilocybin mushrooms and marketing worldwide.

The JV creates an opportunity for the companies to collaborate on the co-development and hosting of virtual conferences and forums focused on educating, informing, and showcasing the potential medicinal benefits of psilocybin mushrooms, including the psilocybin-based products MINE is developing. Additionally, the JV allows for PSYC to serve as one of the primary digital marketing partners for MINE as they move forward with their focus of bringing their products to market.

Oregon also became the first U.S. state to allow medical use of psychedelics last year. Industry experts are hopeful for more regulatory support going forward. If that happens, the industry growth will remarkably accelerate, and psychedelic stocks could soon skyrocket.

MindMed (OTC: MMEDF) offers the broadest and most diversified pipeline of psychedelic drugs in clinical development and R&D. According to the investor deck on MindMed’s website, the Company estimates there is a $100+ billion global total addressable market for psychedelics. 

MindMed recently announced it would establish a digital medicine division known as Albert to research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics. Digital therapeutics are evidence-based therapeutic interventions for patients to prevent, manage, or treat a mental disorder or disease.

MindMed currently has multiple FDA-approved trials going on in multiple jurisdictions and geographies, along with a drug development pipeline based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. Bruce Linton, the Founder and Former Chairman and CEO of Canopy Growth Corporation, serves as a member of MindMed’s Board of Directors. Kevin O’Leary of Shark Tank fame, aka Mr. Wonderful, invested in MindMed in its $24.2 million funding round before going public on Canada’s NEO Exchange. Mr. O’Leary is quoted as saying, “This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?” https://mindmed.co

Numinus Wellness Inc. (OTC: LKYSF) has been granted a license by Health Canada to cultivate, extract, and sell “naturally sourced, sustainable psilocybin”, otherwise known as hallucinogenic magic mushrooms. According to the Company, it’s the only publicly traded company in Canada that is allowed to do so. Numinus aims to make psychedelic-assisted psychotherapy accessible through a network of health centers, or clinics, that provide safe, controlled, and therapeutic environments in which patients can heal and become well.

Numinus Wellness recently acquired Mindspace, a Quebec-based psychedelic programming leader and has plans to support practitioners across 4 clinic locations in Montreal and Vancouver. The Company supports three pathways for exploring psychedelic-assisted psychotherapy: First, practitioners at Mindspace in Montreal now offer Ketamine-assisted psychotherapy, which can be prescribed to address treatment-resistant depression. Second, pending approval of regulatory change, Numinus intends to support practitioners in helping their patients obtain Special Access to psychedelic-assisted therapies for a range of conditions and delivering these through the clinics in both Vancouver and Montreal. Third, Numinus is undertaking two compassionate access clinical trials, which will be conducted by our medical team in our Vancouver clinic. Both trials will be open to Canadian participants. https://numinus.ca

Need More Eyes On Your Company/Stock? Lets Chat Now: https://wa.link/1m9iwf

Recent